Polo-like kinase

Global Polo-Like Kinase 1 (PLK1) Inhibitor Pipeline Insight Report 2021: Key players Involved are Oncoheroes Biosciences, Cyclacel, Cardiff Oncology, Onconova Therapeutics, & Sentinel oncology - ResearchAndMarkets.com

Retrieved on: 
Friday, February 19, 2021
Health, General Health, PLK1, Cell Cycle, PLK, Polo-like kinase, Volasertib

The "Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Polo-Like Kinase 1 (PLK1) Inhibitor pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Polo-Like Kinase 1 (PLK1) Inhibitor R&D.
  • Polo-Like Kinase 1 (PLK1) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference

Retrieved on: 
Monday, November 23, 2020
Clinical medicine, Antineoplastic drugs, Medicine, Health, PLK1, Targeted therapy, Oncology, PLK, Polo-like kinase, Chemotherapy

Beginning today, November 23rd, a pre-recorded fireside chat with company management will be available for viewing anytime through December 3rd by accessing the recording library on the Piper Sandler conference site.

Key Points: 
  • Beginning today, November 23rd, a pre-recorded fireside chat with company management will be available for viewing anytime through December 3rd by accessing the recording library on the Piper Sandler conference site.
  • Cardiff Oncology will also be participating in 1x1 meetings from December 1st 3rd.
  • Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
  • We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.

Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD

Retrieved on: 
Wednesday, April 22, 2020
Medicine, Clinical medicine, Antineoplastic drugs, Cancer, PLK1, Cell Cycle, Chemotherapy, PLK, Targeted therapy, Polo-like kinase

"We are delighted to welcome Jim, Lle and Gary as new directors.

Key Points: 
  • "We are delighted to welcome Jim, Lle and Gary as new directors.
  • "The addition of these three directors brings a wide range of relevant experience and expertise to Trovagene.
  • We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
  • There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.

Serine Threonine Protein Kinase PLK1, Pipeline Review, H2 2019 - Leukemia, Breast Cancer, Hodgkin Lymphona & Rhabdomyosarcoma - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020
Pharmaceutical, Health, Oncology, PLK1, Polo kinase, Polo-like kinase, PLK, STK10, STK38L

The "Serine Threonine Protein Kinase PLK1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Serine Threonine Protein Kinase PLK1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 10 molecules.
  • The latest report SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019, outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene.

Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018

Retrieved on: 
Thursday, October 18, 2018
PLK1, Trovagene, PLK, Polo-like kinase, Biology, Protein kinase inhibitors, Tyrosine kinase receptors

Trovagene continues to advance the development of Onvansertib, its first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, in leukemias, lymphomas and solid tumor cancers.

Key Points: 
  • Trovagene continues to advance the development of Onvansertib, its first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, in leukemias, lymphomas and solid tumor cancers.
  • The conference call will outline the status of all supported clinical studies, as well as provide an update on partnering and collaborations.
  • Trovagene's management team will host a conference call to review its Onvansertib clinical development program and provide a general business update on Wednesday, October 24, 2018 at 8:30 am EDT.
  • To participate in this conference call, please dial 1-877-270-2148 (International Dial 1-412-902-6510) and ask to be joined into the Trovagene call.